George Poste

CIK: 0001180770

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (33.3%)

Position reduction

Option Exercises (M)3 (25.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CAI

Caris Life Sciences, Inc.

Director

EXEL

EXELIXIS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

CAI
Caris Life Sciences, Inc.
May 29, 2026
Award(A)
Direct
1.6K shares at avg. $15.62$25K
EXEL
EXELIXIS, INC.
May 27, 2026
Award(A)
Direct
8.4K shares-
EXEL
EXELIXIS, INC.
May 7, 2026
Sale(S)
Direct
60K shares at avg. $45.71$2.7M
CAI
Caris Life Sciences, Inc.
Aug 11, 2025
Exercise(M)
Direct
125K shares at avg. $2.44$305K
CAI
Caris Life Sciences, Inc.
Aug 11, 2025
Tax Payment(F)
Direct
91.5K shares at avg. $29.75$2.7M
CAI
Caris Life Sciences, Inc.
Aug 11, 2025
Tax Payment(F)
Direct
48K shares at avg. $29.75$1.4M
EXEL
EXELIXIS, INC.
May 29, 2025
Award(A)
Direct
9.8K shares-
EXEL
EXELIXIS, INC.
May 16, 2025
Exercise(M)
Direct
20.6K shares at avg. $19.77$408K
EXEL
EXELIXIS, INC.
May 16, 2025
Sale(S)
Direct
20.6K shares at avg. $45.99$949K
EXEL
EXELIXIS, INC.
Feb 14, 2025
Sale(S)
Direct
15.9K shares at avg. $34.74$551K
EXEL
EXELIXIS, INC.
Feb 14, 2025
Exercise(M)
Direct
15.9K shares at avg. $20.50$325K
EXEL
EXELIXIS, INC.
Nov 1, 2024
Sale(S)
Direct
30K shares at avg. $34.00$1.0M

		Type	Shares	Price		Ownership
May 29, 2026	CAI Caris Life Sciences, Inc.	Award(A)	1,600	$15.62	$24,992	Direct
May 27, 2026	EXEL EXELIXIS, INC.	Award(A)	8,367	-	$0	Direct
May 7, 2026	EXEL EXELIXIS, INC.	Sale(S)	60,000	$45.71	$2,742,600	Direct
Aug 11, 2025	CAI Caris Life Sciences, Inc.	Exercise(M)	125,000	$2.44	$305,000	Direct
Aug 11, 2025	CAI Caris Life Sciences, Inc.	Tax Payment(F)	91,495	$29.75	$2,721,976	Direct
Aug 11, 2025	CAI Caris Life Sciences, Inc.	Tax Payment(F)	48,022	$29.75	$1,428,655	Direct
May 29, 2025	EXEL EXELIXIS, INC.	Award(A)	9,812	-	-	Direct
May 16, 2025	EXEL EXELIXIS, INC.	Exercise(M)	20,634	$19.77	$407,934	Direct
May 16, 2025	EXEL EXELIXIS, INC.	Sale(S)	20,634	$45.99	$948,958	Direct
Feb 14, 2025	EXEL EXELIXIS, INC.	Sale(S)	15,874	$34.74	$551,463	Direct
Feb 14, 2025	EXEL EXELIXIS, INC.	Exercise(M)	15,874	$20.50	$325,417	Direct
Nov 1, 2024	EXEL EXELIXIS, INC.	Sale(S)	30,000	$34.00	$1,020,000	Direct

1-12 of 12 transactions

About POSTE GEORGE

POSTE GEORGE (SEC CIK 0001180770) files insider reports with the SEC as Director of Caris Life Sciences, Inc. (CAI) and Director of EXELIXIS, INC. (EXEL).

Signal8 holds 9 ownership filings by POSTE GEORGE (1 Form 3, 8 Form 4), filed between Nov 5, 2024 and Jun 2, 2026. Those filings report 12 transactions, from Nov 1, 2024 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on POSTE GEORGE's filings is in IRVING, TX.

Recent filings by POSTE GEORGE

May 29, 2026: Grant or award of CAI shares (Form 4, code A).
May 27, 2026: Grant or award of EXEL shares (Form 4, code A).
May 7, 2026: Open-market sale of EXEL shares (Form 4, code S).
Aug 11, 2025: Option exercise of CAI shares (Form 4, code M).
Aug 11, 2025: Tax withholdings of CAI shares (2 lines, Form 4, code F).

Other insiders filing for Caris Life Sciences, Inc. (CAI)

How to read Form 4 transaction codes